ReeHu Investment

ReeHu is a leading Chinese biotechnology company specializing in the development and industrialization of recombinant humanized collagen through synthetic biology. The company's core technology platform enables the production of high-purity collagen proteins that closely mimic human sequences, ensuring high biocompatibility and safety for medical applications. ReeHu's product portfolio primarily targets the medical aesthetics and regenerative medicine markets, including injectable fillers, wound dressings, and skin repair solutions. With significant backing from prominent investors like Sequoia China and IDG Capital, the company has established large-scale GMP manufacturing facilities in Shanghai. ReeHu is recognized as a pioneer in the recombinant collagen sector, providing innovative materials for both clinical and cosmetic use. The company continues to expand its pipeline into orthopedics and other regenerative medicine fields.